Palisade Bio says Phase 1b study shows early clinical, biomarker gains for PALI-2108 in fibrostenotic Crohn’s disease

Bitget2026/09/28 12:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Palisade Bio flagged new Phase 1b clinical and translational readouts for PALI-2108 ahead of UEG Week 2026 in Barcelona.
Results will be presented in the future, including an oral talk on fibrostenotic Crohn’s disease on Oct. 18, 2026.
Data are set to show early endoscopic improvement, biomarker shifts consistent with PDE4 target engagement, favorable safety, and gut-targeted exposure.
Separate presentations are expected to indicate rapid clinical response in ulcerative colitis and progress on a biomarker to predict responders.
PALI-2108 is moving into Phase 2 development in ulcerative colitis and Crohn’s disease as a once-daily oral therapy candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280850PRIMZONEFULLFEED9834633) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Palisade Bio says Phase 1b study shows early clinical, biomarker gains for PALI-2108 in fibrostenotic Crohn’s disease

You may also like

Crypto prices